Multiple Sclerosis Misdiagnosis: A Persistent Problem to Solve

María I Gaitán, Jorge Correale, María I Gaitán, Jorge Correale

No abstract available

Keywords: McDonald criteria; diagnostic error; misdiagnosis; multiple sclerosis; multiple sclerosis mimics.

References

    1. Yamout BI, Khoury SJ, Ayyoubi N, Doumiati H, Fakhreddine M, Ahmed SF, et al. . Alternative diagnoses in patients referred to specialized centers for suspected MS. Mult Scler Relat Disord. (2017) 18:85–9. 10.1016/j.msard.2017.09.016
    1. Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, et al. . The contemporary spectrum of multiple sclerosis misdiagnosis: a multicenter study. Neurology. (2016) 87:1393–9. 10.1212/WNL.0000000000003152
    1. Solomon AJ, Klein EP, Bourdette D. “Undiagnosing” multiple sclerosis: the challenge of misdiagnosis in MS. Neurology. (2012) 78:1986–91. 10.1212/WNL.0b013e318259e1b2
    1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. (2018) 17:162–73. 10.1016/S1474-4422(17)30470-2
    1. Rudick RA, Schiffer RB, Schwetz KM, Herndon RM. Multiple sclerosis. The problem of incorrect diagnosis. Arch Neurol. (1986) 43:578–83.
    1. Poser CM. Misdiagnosis of multiple sclerosis and beta-interferon. Lancet. (1997) 349:1916. 10.1016/S0140-6736(05)63920-7
    1. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. (2001) 50:121–7. 10.1002/ana.1032
    1. Carmosino MJ, Brousseau KM, Arciniegas DB, Corboy JR. Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral. Arch Neurol. (2005) 62:585–90. 10.1001/archneur.62.4.585
    1. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al. . Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. (2008) 14:1157–74. 10.1177/1352458508096878
    1. Boissy AR, Ford PJ. A touch of MS: therapeutic mislabeling. Neurology. (2012) 78:1981–5. 10.1212/WNL.0b013e318259e0ec
    1. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. (2012) 18:113–5. 10.1177/1352458511431973
    1. Cortese R, Magnollay L, Tur C, Abdel-Aziz K, Jacob A, De Angelis F, et al. . Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. Neurology. (2018) 90:e1183–e1190. 10.1212/WNL.0000000000005256
    1. Maggi P, Absinta M, Grammatico M, Vuolo L, Emmi G, Carlucci G, et al. . Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. (2018) 83:283–94. 10.1002/ana.25146
    1. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. . Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. (2005) 62:865–70. 10.1001/archneur.62.6.865
    1. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. . Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. (2011) 306:82–90. 10.1016/j.jns.2011.03.038
    1. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. (2016) 13:280. 10.1186/s12974-016-0718-0
    1. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. (2005) 202:473–7. 10.1084/jem.20050304
    1. Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, et al. . Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry. (2016) 87:1257–9. 10.1136/jnnp-2015-312676
    1. Masuda S, Mori M, Arai K, Uzawa A, Muto M, Uchida T, et al. . Epstein-Barr virus persistence and reactivation in neuromyelitis optica. J Neurol Neurosurg Psychiatry. (2015) 86:1137–42. 10.1136/jnnp-2014-308095
    1. Kakalacheva K, Regenass S, Wiesmayr S, Azzi T, Berger C, Dale RC, et al. . Infectious mononucleosis triggers generation of IgG auto-antibodies against native myelin oligodendrocyte glycoprotein. Viruses. (2016) 8:E51. 10.3390/v8020051
    1. Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, et al. . The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. (2017) 264:453–66. 10.1007/s00415-016-8360-4
    1. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. (2013) 84:909–14. 10.1136/jnnp-2012-304695
    1. Rovira A, Wattjes MP, Tintore M, Tur C, Yousry TA, Sormani MP, et al. . Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. (2015) 11:471–82. 10.1038/nrneurol.2015.106
    1. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. (2004) 364:2106–12. 10.1016/S0140-6736(04)17551-X
    1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. (2018) 391:1622–36. 10.1016/S0140-6736(18)30481-1
    1. Brecht I, Weissbrich B, Braun J, Toyka KV, Weishaupt A, Buttmann M. Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis. PLoS ONE. (2012) 7:e40431. 10.1371/journal.pone.0040431
    1. Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler. (2011) 17:1185–93. 10.1177/1352458511408991
    1. Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, Giovannoni G, et al. . The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler. (2013) 19:162–6. 10.1177/1352458512449682
    1. Deuschle K, Hofmann J, Otto C, Bellmann-Strobl J, Scherner O, Klumbies K, et al. . Are there Epstein-Barr virus seronegative patients with multiple sclerosis? Mult Scler. (2013) 19:1242–3. 10.1177/1352458512472751
    1. Pakpoor J, Ramagopalan SV. Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: yes. Mult Scler. (2013) 19:1690–1. 10.1177/1352458513506505

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner